AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

1. (Original): A disodium salt of a delivery agent having the formula



wherein

R^1, R^2, R^3, and R^4 are independently hydrogen, -OH, $-NR^6R^7$, halogen, C_1-C_4 alkyl, or C_1-C_4 alkoxy;

R^5 is a substitued or unsubstituted C_2-C_{16} alkylene, substituted or unsubstituted C_2-C_{16} alkenylene, substituted or unsubstituted C_1-C_{12} alkyl(arylene), or substituted or unsubstituted aryl(C_1-C_{12} alkylene); and

R^6 and R^7 are independently hydrogen, oxygen, or C_1-C_4 alkyl.

2. (Cancelled)

3. (Original): The disodium salt of claim 1, wherein the delivery agent is *N*-(10-[2-hydroxybenzoyl]amino)decanoic acid.

4. (Original): The disodium salt of claim 1, wherein the delivery agent is sodium *N*-(8-[2-hydroxybenzoyl]amino)caprylic acid.

5. (Original): An ethanol solvate of the disodium salt of claim 1.

6. (Cancelled)

7. (Original): The ethanol solvate of claim 5, wherein the delivery agent is *N*-(10-[2-hydroxybenzoyl]amino)decanoic acid.

8. (Original): The ethanol solvate of claim 5, wherein the delivery agent is sodium *N*-(8-[2-hydroxybenzoyl]amino)caprylic acid.

9. (Original): A monohydrate of the disodium salt of claim 1.

10. (Cancelled)

11. (Original): The monohydrate of claim 9, wherein the delivery agent is *N*-(10-[2-hydroxybenzoyl]amino)decanoic acid.

12. (Original): The monohydrate of claim 9, wherein the delivery agent is sodium *N*-(8-[2-hydroxybenzoyl]amino)caprylic acid.

13. (Original): A composition comprising at least about 50% by weight of the disodium salt of claim 1, based upon 100% total weight of delivery agent and salts thereof in the composition.

14. (Original): The composition of claim 13, wherein the composition comprises at least about 90% by weight of the disodium salt, based upon 100% total weight of delivery agent and salts thereof in the composition.

15. (Original): A composition comprising:

(a) the disodium salt of claim 1, ethanol solvate thereof, or monohydrate thereof; and

(b) at least one active agent.

16. (Original): The composition of claim 15, wherein the composition comprises at least about 50% by weight of the disodium salt, based upon 100% total weight of delivery agent and salts thereof in the composition.

17. (Original): The composition of claim 16, wherein the composition comprises at least about 90% by weight of the disodium salt,

based upon 100% total weight of delivery agent and salts thereof in the composition.

18. (Original): The composition of claim 15, wherein the composition comprises at least about 90% by weight of the monohydrate, based upon 100% total weight of hydrate of the disodium salt of the delivery agent in the composition.

19. (Original): The composition of claim 15, wherein the active agent is selected from the group consisting of growth hormones; human growth hormones; recombinant human growth hormones; bovine growth hormones; porcine growth hormones; growth hormone-releasing hormones; interferons; α-interferon; β-interferon; γ-interferon; interleukin-1; interleukin-2; insulin; porcine insulin; bovine insulin; human insulin; human recombinant insulin; insulin-like growth factor; IGF-1; heparin; unfractionated heparin; heparinoids; dermatans; chondroitins; low molecular weight heparin; very low molecular weight heparin; ultra low molecular weight heparin; calcitonin; salmon calcitonin; eel calcitonin; human calcitonin; porcine calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin; gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium; sodium chromoglycate; disodium chromoglycate; vancomycin; desferrioxamine; parathyroid hormone; fragments of parathyroid hormone; antimicrobials; anti-fungal agents; vitamins; analogs, fragments, mimetics and polyethylene glycol-modified derivatives of these compounds; and any combination thereof.

20. (Original): The composition of claim 15, wherein the active agent is selected from the group consisting of heparin and calcitonin.

21. (Original): A dosage unit form comprising:

(a) the composition of claim 15; and

(b) (i) an excipient,

(ii) a diluent,

(iii) a disintegrant,

(iv) a lubricant,

(v) a plasticizer,

(vi) a colorant,

(vii) a dosing vehicle, or

(viii) any combination thereof.

22. (Original): A solid dosage unit form comprising a lyophilized mixture comprising

(a) the disodium salt of claim 1; and

(b) at least one active agent.

Claims 23-28 (Canceled)

29. (Previously Presented): A method for administering salmon calcitonin to an animal in need thereof, the method comprising administering orally to the animal a composition comprising:

(a) N-(5-chlorosalicyloyl)-8-aminocaprylic acid, wherein N-(5-chlorosalicyloyl)-8-aminocaprylic acid comprises at least about 96% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid; and

(b) salmon calcitonin.

30. (New): The method of claim 29, wherein the weight ratio of calcitonin to the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid is from about 1:300 to about 1:700.

31. (New): The method of claim 29, wherein the weight ratio of calcitonin to the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid is about 1:500.

32. (New): The method of claim 29, wherein the composition is a dosage unit form.

33. (New): The method of claim 30, wherein the composition is a dosage unit form.

34. (New): The method of claim 31, wherein the composition is a dosage unit form.

35. (New): The method of claim 32, wherein the dosage unit form further comprises:

(i) an excipient,
(ii) a diluent,
(iii) a disintegrant,
(iv) a lubricant,
(v) a plasticizer,
(vi) a colorant,
(vii) a dosing vehicle, or
(viii) any combination thereof.

36. (New): The method of claim 33, wherein the dosage unit form further comprises:

(i) an excipient,
(ii) a diluent,

(iii) a disintegrant,
(iv) a lubricant,
(v) a plasticizer,
(vi) a colorant,
(vii) a dosing vehicle, or
(viii) any combination thereof.

37. (New): The method of claim 34, wherein the dosage unit form further comprises:

(i) an excipient,
(ii) a diluent,
(iii) a disintegrant,
(iv) a lubricant,
(v) a plasticizer,
(vi) a colorant,
(vii) a dosing vehicle, or
(viii) any combination thereof.

38. (New): The method of claim 32, wherein the dosage unit form is a tablet.

39. (New): The method of claim 33, wherein the dosage unit form is a tablet.

40. (New): The method of claim 34, wherein the dosage unit form is a tablet.

41. (New): The method of claim 32, wherein the dosage unit form is a capsule.

42. (New): The method of claim 33, wherein the dosage unit form is a capsule.

43. (New): The method of claim 34, wherein the dosage unit form is a capsule.

44. (New): The method of claim 29, wherein the animal is a human.

45. (New): The method of claim 30, wherein the animal is a human.

46. (New): The method of claim 31, wherein the animal is a human.

47. (New): The method of claim 32, wherein the animal is a human.

48. (New): The method of claim 33, wherein the animal is a human.

49. (New): The method of claim 34, wherein the animal is a human.

50. (New): The method of claim 35, wherein the animal is a human.

51. (New): The method of claim 36, wherein the mammal is a human.

52. (New): The method of claim 37, wherein the mammal is a human.

53. (New): The method of claim 38, wherein the mammal is a human.

54. (New): The method of claim 39, wherein the mammal is a human.

55. (New): The method of claim 40, wherein the mammal is a human.

56. (New): The method of claim 41, wherein the mammal is a human.

57. (New): The method of claim 42, wherein the mammal is a human.

58. (New): The method of claim 43, wherein the mammal is a human.

59. (New): A disodium salt of the delivery agent *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid.

60. (New): An ethanol solvate of the disodium salt of claim 59.

61. (New): A monohydrate of the disodium salt of claim 59.

62. (New): A pharmaceutical composition comprising (a) at least about 50% by weight of the disodium salt of claim 59, based upon 100% total weight of the delivery agent *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and (b) at least one active agent.

63. (Original): The pharmaceutical composition of claim 62, wherein the composition comprises at least about 90% by weight of the disodium salt, based upon 100% total weight of delivery agent *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition.

64. (New): The pharmaceutical composition of claim 62, wherein the active agent is selected from the group consisting of growth hormones; human growth hormones; recombinant human growth hormones; bovine growth hormones; porcine growth hormones; growth hormone-releasing hormones; interferons; α-interferon; β-interferon; γ-interferon; interleukin-1; interleukin-2; insulin; porcine insulin; bovine insulin; human insulin; human recombinant insulin; insulin-like growth factor; IGF-1; heparin; unfractionated heparin; heparinoids; dermatans; chondroitins; low molecular weight heparin; very low molecular weight heparin; ultra low molecular weight heparin; calcitonin; salmon calcitonin; eel calcitonin; human calcitonin; porcine calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin; gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium; sodium chromoglycate; disodium chromoglycate; vancomycin; desferrioxamine; parathyroid hormone;

fragments of parathyroid hormone; antimicrobials; anti-fungal agents; vitamins; analogs, fragments, mimetics and polyethylene glycol-modified derivatives of these compounds; and any combination thereof.

65. (New): The pharmaceutical composition of claim 62, wherein the active agent is calcitonin.

66. (New): A dosage unit form comprising:

(a) the pharmaceutical composition of claim 62; and

(b) (i) an excipient,

(ii) a diluent,

(iii) a disintegrant,

(iv) a lubricant,

(v) a plasticizer,

(vi) a colorant,

(vii) a dosing vehicle, or

(viii) any combination thereof.